

## Special Issue

# Nucleotides Delivery for Cancer Treatment

### Message from the Guest Editor

The discovery of the RNA interference mechanism prompted the use of oligonucleotides as therapeutic agents for the treatment of several diseases, including cancer. Nevertheless, the peculiar physico-chemical features of the short RNA or DNA molecules and the complex physiopathology of tumour pose a hurdle to the efficacious delivery of oligonucleotides to cancer cells. To overcome these problems, scientists developed different types of carriers, such as viral vectors, exosomes, polymer- and lipid-based systems. This Special Issue aims to highlight novel approaches to the delivery of oligonucleotides to cancer, with attention to all the aspects of the nanomedicine development, from their synthesis and physico-chemical characterization, to the understanding of their biological properties and the in vivo efficacy. We are looking forward to receiving original research papers as well as review articles with expert opinion on the state of art and future perspective on the field.

---

### Guest Editor

Dr. Anna Scomparin

Department of Drug Science and Technology, University of Turin, 10125 Turin, Italy

---

### Deadline for manuscript submissions

closed (31 December 2021)



## Pharmaceutics

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.5  
CiteScore 10.0  
Indexed in PubMed



[mdpi.com/si/48760](https://mdpi.com/si/48760)

*Pharmaceutics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)

[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





# Pharmaceutics

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.5  
CiteScore 10.0  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



## About the Journal

### Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

---

### Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.7 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the second half of 2025).